| Previous Close | 148.40 |
| Open | 148.40 |
| Bid | 147.25 x 1200 |
| Ask | 147.79 x 900 |
| Day's Range | 146.50 - 149.25 |
| 52 Week Range | 109.16 - 157.00 |
| Volume | 4,835,493 |
| Avg. Volume | 6,887,310 |
| Market Cap | 388.473B |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | 25.96 |
| EPS (TTM) | 5.68 |
| Earnings Date | Oct. 13, 2020 |
| Forward Dividend & Yield | 4.04 (2.72%) |
| Ex-Dividend Date | Aug. 24, 2020 |
| 1y Target Est | 166.06 |
- Editor's PickYahoo Finance Video
‘We need to make sure that the science and safety is there’ so people can trust the vaccine: doctor
The conversation around pricing vaccinations and distribution is ramping up as more pharmaceuticals announce positive test results. Dr. Rob Davidson, a West Michigan ER doctor and the Executive Director of the Committee to Protect Medicare, joins The Final Round panel to discuss his views on the coronavirus vaccine front.
- Baystreet
More Highs for TSX
Canada's main stock index scaled a five-month high on Thursday as a surge in shares of drugmaker Bausch ...
- Reuters
U.S. FDA approves GlaxoSmithKline's blood cancer drug
The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's experimental treatment for a common form of blood cancer. GSK's belantamab mafodotin, or BLENREP, was approved for treating adults with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, the drugmaker said in a statement. Multiple myeloma is the second most common form of blood cancer in the U.S. and is generally considered treatable, but not curable.
